We then used the three genes (DNMT3A, SET8 and DOT1L) identified as independent prognostic factors in patients with DLBCL to develop a risk score (EpiScore) based on their expression level. The gene discussed is DOT1L; the disease is diffuse large B-cell lymphoma.